• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

幽门螺杆菌:临床实践中当前治疗选择的综述

Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.

作者信息

Roberts Logan T, Issa Peter P, Sinnathamby Evan S, Granier Mallory, Mayeux Holly, Eubanks Treniece N, Malone Kevin, Ahmadzadeh Shahab, Cornett Elyse M, Shekoohi Sahar, Kaye Alan D

机构信息

LSUHSC-New Orleans School of Medicine, 1901 Perdido Street, New Orleans, LA 70112, USA.

Department of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.

出版信息

Life (Basel). 2022 Dec 6;12(12):2038. doi: 10.3390/life12122038.

DOI:10.3390/life12122038
PMID:36556402
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9785457/
Abstract

BACKGROUND

When prescribing antibiotics, infection eradication rates, local resistance rates, and cost should be among the most essential considerations. is among the most common infections worldwide, and it can lead to burdensome sequela for the patient and the healthcare system, without appropriate treatment. Due to constantly fluctuating resistance rates, regimens must be constantly assessed to ensure effectiveness.

METHODS

This was a narrative review. The sources for this review are as follows: searching on PubMed, Google Scholar, Medline, and ScienceDirect; using keywords: , Treatment Options, Clinical Practice.

RESULTS

Multiple antibiotics are prescribed as part of the regimen to thwart high resistance rates. This can lead to unwanted adverse reactions and adherence issues, due to the amount and timing of medication administration, which also may contribute to resistance. Single-capsule combination capsules have reached the market to ease this concern, but brand-only may be problematic for patient affordability. Due to the previously mentioned factors, effectiveness and affordability must be equally considered.

CONCLUSIONS

This review will utilize guidelines to discuss current treatment options and give cost considerations to elicit the most effective regimen for the patient.

摘要

背景

在开具抗生素处方时,感染根除率、局部耐药率和成本应是最重要的考虑因素。在全球范围内是最常见的感染之一,如果没有适当的治疗,它会给患者和医疗系统带来沉重的后遗症负担。由于耐药率不断波动,必须不断评估治疗方案以确保有效性。

方法

这是一篇叙述性综述。本综述的资料来源如下:在PubMed、谷歌学术、Medline和科学Direct上进行搜索;使用关键词:治疗选择、临床实践。

结果

多种抗生素作为治疗方案的一部分被开具,以应对高耐药率。由于药物给药的数量和时间,这可能导致不良的不良反应和依从性问题,这也可能导致耐药性。单胶囊组合胶囊已投放市场以缓解这一担忧,但仅品牌药可能对患者的可承受性存在问题。由于上述因素,有效性和可承受性必须同等考虑。

结论

本综述将利用指南讨论当前的治疗选择,并给出成本考量,以确定对患者最有效的治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/2bcb1a0c12a3/life-12-02038-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/add9d51aa129/life-12-02038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/7043dc883d15/life-12-02038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/c6e506951525/life-12-02038-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/2bcb1a0c12a3/life-12-02038-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/add9d51aa129/life-12-02038-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/7043dc883d15/life-12-02038-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/c6e506951525/life-12-02038-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0066/9785457/2bcb1a0c12a3/life-12-02038-g004.jpg

相似文献

1
Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.幽门螺杆菌:临床实践中当前治疗选择的综述
Life (Basel). 2022 Dec 6;12(12):2038. doi: 10.3390/life12122038.
2
Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.在一个抗生素高耐药率的欧洲地区,幽门螺杆菌根除方案:成本效益分析。
Helicobacter. 2020 Feb;25(1):e12666. doi: 10.1111/hel.12666. Epub 2019 Nov 6.
3
Eradication rate of Helicobacter Pylori infection is directly influenced by adherence to therapy in children.儿童幽门螺杆菌感染的根除率直接受治疗依从性的影响。
Helicobacter. 2017 Aug;22(4). doi: 10.1111/hel.12383. Epub 2017 Mar 17.
4
Optimum duration of regimens for Helicobacter pylori eradication.幽门螺杆菌根除治疗方案的最佳疗程
Cochrane Database Syst Rev. 2013 Dec 11;2013(12):CD008337. doi: 10.1002/14651858.CD008337.pub2.
5
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.在临床实践中,基于质子泵抑制剂的三联疗法治疗幽门螺杆菌感染失败时的治疗选择。
Aliment Pharmacol Ther. 1999 Apr;13(4):489-96. doi: 10.1046/j.1365-2036.1999.00504.x.
6
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.欧洲幽门螺杆菌管理注册研究:单胶囊铋剂四联疗法在真实临床实践中有效。
United European Gastroenterol J. 2021 Feb;9(1):38-46. doi: 10.1177/2050640620972615. Epub 2021 Feb 11.
7
Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.2018年幽门螺杆菌感染治疗的药理学考量及逐步建议
Minerva Gastroenterol Dietol. 2018 Sep;64(3):310-321. doi: 10.23736/S1121-421X.18.02492-3. Epub 2018 Mar 30.
8
Eradication of in Iran: A Review.伊朗的根除:一项综述。
Middle East J Dig Dis. 2018 Jan;10(1):5-17. doi: 10.15171/mejdd.2017.84. Epub 2017 Sep 21.
9
Effectiveness and safety of furazolidone-containing quadruple regimens in patients with Helicobacter pylori infection in real-world practice.在真实世界实践中,含呋喃唑酮的四联方案治疗幽门螺杆菌感染的有效性和安全性。
Helicobacter. 2019 Aug;24(4):e12591. doi: 10.1111/hel.12591. Epub 2019 May 20.
10
Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance.抗生素耐药性不断增加的时代下针对[具体病症,原文缺失]的新型有效治疗方案
Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017.

引用本文的文献

1
Co-Infection Dynamics of and Helminths: A Double-Edged Sword.与蠕虫的共同感染动态:一把双刃剑。 (你提供的原文中“Co-Infection Dynamics of and Helminths”存在信息缺失,推测完整原文可能是“Co-Infection Dynamics of Viruses and Helminths”,这里是按照推测完整后的内容翻译的,你可根据实际情况调整。)
Int J Mol Sci. 2025 Aug 19;26(16):8001. doi: 10.3390/ijms26168001.
2
Challenges and Prospects for Eradication of : Targeting Virulence Factors, Metabolism, and Vaccine Innovation.根除的挑战与前景:靶向毒力因子、代谢及疫苗创新
Pathogens. 2025 Jun 21;14(7):619. doi: 10.3390/pathogens14070619.
3
Exploring the bioactive compounds of leaves: phytol's role in combatting antibiotic-resistant bacteria.

本文引用的文献

1
Amoxicillin-associated Stevens-Johnson syndrome or toxic epidermal necrolysis: systematic review.阿莫西林相关的史蒂文斯-约翰逊综合征或中毒性表皮坏死松解症:系统评价
J Chemother. 2023 Apr;35(2):75-86. doi: 10.1080/1120009X.2022.2051128. Epub 2022 Mar 14.
2
Protection of Anaerobic Microbes from Processing Stressors Using Metal-Phenolic Networks.利用金属-酚醛网络保护厌氧微生物免受加工胁迫。
J Am Chem Soc. 2022 Feb 16;144(6):2438-2443. doi: 10.1021/jacs.1c09018. Epub 2021 Dec 9.
3
Overview of Infection: Clinical Features, Treatment, and Nutritional Aspects.
探索树叶的生物活性化合物:叶绿醇在对抗抗生素耐药细菌中的作用。
Front Cell Infect Microbiol. 2025 Jul 7;15:1564787. doi: 10.3389/fcimb.2025.1564787. eCollection 2025.
4
Targeting Urease: A Promising Adjuvant Strategy for Effective Eradication.靶向脲酶:一种有望实现有效根除的辅助策略。
ACS Omega. 2025 Jul 4;10(27):28643-28669. doi: 10.1021/acsomega.5c02725. eCollection 2025 Jul 15.
5
Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori.抗生素应激会影响幽门螺杆菌产生的细胞外囊泡的分泌及物理化学特性。
J Antimicrob Chemother. 2025 Jul 1;80(7):2032-2043. doi: 10.1093/jac/dkaf172.
6
Anti-urease therapy: a targeted approach to mitigating antibiotic resistance in Helicobacter pylori while preserving the gut microflora.抗脲酶疗法:一种在保留肠道微生物群的同时减轻幽门螺杆菌抗生素耐药性的靶向方法。
Gut Pathog. 2025 May 28;17(1):37. doi: 10.1186/s13099-025-00708-1.
7
Clinical Effectiveness of Penicillin-Free Therapies in First-Line and Rescue Treatments for : A Systematic Review.无青霉素疗法在一线和挽救治疗中的临床疗效:一项系统评价
Antibiotics (Basel). 2025 May 8;14(5):476. doi: 10.3390/antibiotics14050476.
8
Halogenated -Benzylbenzisoselenazolones Efficiently Inhibit Ureolysis .卤代苄基苯并异硒唑酮可有效抑制尿素分解。
ACS Med Chem Lett. 2025 Mar 29;16(4):675-680. doi: 10.1021/acsmedchemlett.5c00057. eCollection 2025 Apr 10.
9
Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.阿奇霉素与克拉霉素治疗幽门螺杆菌感染的疗效比较
Cureus. 2024 Oct 21;16(10):e72033. doi: 10.7759/cureus.72033. eCollection 2024 Oct.
10
Liposomal Drug Delivery against Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.在强化治疗中使用呋喃唑酮和N-乙酰半胱氨酸的脂质体药物递送。 (注:原文against后内容缺失,翻译可能存在一定局限性)
Pharmaceutics. 2024 Aug 26;16(9):1123. doi: 10.3390/pharmaceutics16091123.
感染概述:临床特征、治疗及营养方面
Diseases. 2021 Sep 23;9(4):66. doi: 10.3390/diseases9040066.
4
Efficacy of levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) regimen compared with standard triple therapy to eradicate infection: a prospective randomized study from a tertiary hospital in India.左氧氟沙星、奥美拉唑、硝唑尼特和强力霉素(LOAD)方案与标准三联疗法根除感染的疗效比较:一项来自印度一家三级医院的前瞻性随机研究。
Gastroenterol Hepatol Bed Bench. 2021 Fall;14(4):342-348.
5
Old and New Beta-Lactamase Inhibitors: Molecular Structure, Mechanism of Action, and Clinical Use.新型与传统β-内酰胺酶抑制剂:分子结构、作用机制及临床应用
Antibiotics (Basel). 2021 Aug 17;10(8):995. doi: 10.3390/antibiotics10080995.
6
Sitafloxacin for Third-Line Eradication: A Systematic Review.西他沙星用于三线根除治疗:一项系统评价
J Clin Med. 2021 Jun 20;10(12):2722. doi: 10.3390/jcm10122722.
7
Concomitant Therapy versus Triple Therapy: Efficacy in H. Pylori Eradication and Predictors of Treatment Failure.联合疗法与三联疗法:幽门螺杆菌根除疗效及治疗失败的预测因素
J Coll Physicians Surg Pak. 2021 Feb;31(2):128-131. doi: 10.29271/jcpsp.2021.02.128.
8
Adverse Effects Associated with Proton Pump Inhibitor Use.与使用质子泵抑制剂相关的不良反应。
Cureus. 2021 Jan 18;13(1):e12759. doi: 10.7759/cureus.12759.
9
The Minimum Inhibitory Concentration of Antibiotics: Methods, Interpretation, Clinical Relevance.抗生素的最低抑菌浓度:方法、解读及临床相关性
Pathogens. 2021 Feb 4;10(2):165. doi: 10.3390/pathogens10020165.
10
AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review.AGA 临床实践更新:难治性幽门螺杆菌感染的管理:专家综述。
Gastroenterology. 2021 Apr;160(5):1831-1841. doi: 10.1053/j.gastro.2020.11.059. Epub 2021 Jan 29.